Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page
- Check7 days agoChange DetectedAdded Naples, Italy 80131 to the locations and removed Napoli, Italy 80131 from the locations.SummaryDifference0.0%

- Check14 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous revision v3.4.3.SummaryDifference0.0%

- Check21 days agoChange DetectedThe page now displays Revision: v3.4.3. The previous Revision: v3.4.2 has been removed.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedFallopian tube cancer is now listed as a condition and the Genetic and Rare Diseases Information Center resource is added; the page version updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check57 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a glossary toggle and updated metadata labels, including the 'Last Update Submitted that Met QC Criteria' entry, 'No FEAR Act Data' capitalization, and the revision/version to v3.4.0. These are minor UI/metadata updates and do not affect the study content or results; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.